| Literature DB >> 25130838 |
Hua Yang1, Xiao-Ping Han1, Bao-Jing Li2, Lu Sun3, Hai-Yan Zhu1, Fei Li1, Quan-Shun Wang1, Wen-Rong Huang1, Jian Bo1, Yu Zhao1, Hong-Hua Li1, Shu-Hong Wang1, Li Yu1, Yu Jing4.
Abstract
Purpose of this study was to analyse the characteristics of clinical, iconographical, pathological and treatment methods of Langerhans cell histiocytosis (LCH), so as to improve the diagnosis and treatment level of this disease. The clinical data of 35 LCH patients were studied retrospectively. These patients were divided into 2 groups according to age <14 years old and ≥ 14 years old. The clinical symptoms were analysed and the signs, imageology and pathology manifestation and treatment results were evaluated. The results showed that LCH clinical manifestations were diverse and complex. Surgical treatment for patients with single system involvement of LCH was better than that of multi-system involvement of LCH (MS-LCH). For the latter, combined chemotherapy effects was better. After 3-year follow-up, 1-year OS was 94% ± 4%, 2-years OS was 91% ± 5%, 3-year OS was 86% ± 7%. 3 years OS of group <14 years old and ≥ 14 years old was 94% ± 6% and 81% ± 10% respectively. The OS of former was better than that of the later, but because a small number of cases, this difference was not statistically significant. It is concluded that LCH is easy to be misdiagnosed, the pathological biopsy is the gold standard of LCH diagnosis. The PET-CT can be of great help in identifying stages and finding lesion areas of the disease. Pulmonary Langerhans cell histiocytosis (PLCH) is more common in adult. Combined chemotherapy can improve the prognosis of the patients. The treatment methods should be choosed according to the stage and classification of disease.Entities:
Mesh:
Year: 2014 PMID: 25130838 DOI: 10.7534/j.issn.1009-2137.2014.04.042
Source DB: PubMed Journal: Zhongguo Shi Yan Xue Ye Xue Za Zhi ISSN: 1009-2137